Loading the full library. You can read the first studies below.
How this library is organized
Studies default to publication date, newest first, not the date a summary was added. Choose Most relevant for human-first editorial reading order, not an effectiveness or quality ranking. Design, topic and intervention-candidate labels assist discovery; they are not formal appraisals. Result-direction and sample-size filters only use existing verified metadata; missing values are excluded when those filters are active. Study counts are publications, not unique trials or participants.
Human · Controlled study · 2026-10-27
A controlled mechanistic study examined whether muscle disuse reduces synthesis or increases breakdown, accounting for shrinking muscle-protein pools.
Population, studied exposure & key finding
- Population
- Fourteen healthy young women, average age 21.
- Studied dose & duration
- One leg underwent 10 days of unloading; the opposite leg performed resistance exercise. Deuterated water, MRI and mathematical models assessed turnover and muscle size.
- Finding
- Unloading reduced muscle volume and mixed/myofibrillar protein synthesis. Model-derived breakdown did not increase. Accounting for the shrinking protein pool preserved this conclusion. Integrated synthesis in the exercised leg did not rise above baseline.
Abstract summarized · Verified intervention · Summary quality not appraised
Human · Randomized trial · 2026-10-26
A randomized phase 2 trial compared weekly lonapegsomatropin with daily somatropin for growth in Turner syndrome.
Population, studied exposure & key finding
- Population
- 49 prepubertal children were enrolled and dosed, according to the publication.
- Studied dose & duration
- Weekly subcutaneous lonapegsomatropin starting doses: 0.24, 0.30 or 0.36 mg hGH/kg/week. Daily somatropin totaled 0.35 mg/kg/week, not per day; 52 weeks.
- Finding
- Primary week-26 annualized height velocity was 9.23–10.36 cm/year across weekly starting-dose groups versus 10.86 with daily treatment. Secondary week-52 rates were 9.05 pooled versus 9.04 cm/year. The abstract reported similar tolerability.
Abstract summarized · Verified intervention · Summary quality not appraised
Human · Randomized trial · 2026-10-26
A phase 2b randomized trial tested intranasal mebufotenin benzoate for treatment-resistant depression.
Population, studied exposure & key finding
- Population
- 193 adults with moderate-to-severe depression after inadequate response to prior antidepressant treatments.
- Studied dose & duration
- One intranasal dose: 8 mg, 12 mg or 0.3 mg low-dose comparator, with psychological support and antidepressant washout as needed; eight-week follow-up.
- Finding
- Primary day-29 depression-score difference for 12 versus 0.3 mg: −5.3 MADRS points (95% CI −8.9 to −1.8). Adverse events affected 85% versus 73%; most events across groups were mild or moderate.
Abstract summarized · Verified intervention · Summary quality not appraised
Human · Randomized trial · 2026-10-26
A randomized acute-feeding trial compared corn, pea/corn and milk proteins for muscle protein synthesis.
Population, studied exposure & key finding
- Population
- 48 healthy older adults, average age 68; equal numbers of men and women.
- Studied dose & duration
- One oral 20 g protein serving versus low-energy nonprotein placebo. Participants exercised one leg; the other provided a resting comparison.
- Finding
- Protein-synthesis increases from baseline were 216 percent with corn, 217 percent with pea/corn, 138 percent with milk and 77 percent with placebo. Protein groups exceeded placebo; no active-protein difference was detected. Exercise further increased synthesis.
Abstract summarized · Verified intervention · Summary quality not appraised
Human · Randomized trial · 2026-10-24
An exploratory randomized study tested creatine with resistance training for cognition, sleep and perimenopause symptoms.
Population, studied exposure & key finding
- Population
- 51 perimenopausal women, average age 46, assigned to creatine, placebo or a nontraining control.
- Studied dose & duration
- Oral creatine monohydrate 20 g/day for 5 days, then approximately 4.5 g/day for six weeks; creatine and placebo groups trained twice weekly.
- Finding
- Sleep consistency at week 6 favored creatine by 7.4 percentage points versus placebo after baseline adjustment (p=0.015). Prefrontal oxygenation increased, but Stroop reaction-time improvement did not differ between groups.
Abstract summarized · Verified intervention · Summary quality not appraised
Human · Randomized trial · 2026-10-21
A secondary trial analysis examined semaglutide effects on modeled decision strategies, not general intelligence.
Population, studied exposure & key finding
- Population
- 72 adults with major depression, overweight/obesity and cognitive difficulties; semaglutide versus placebo.
- Studied dose & duration
- Oral semaglutide titrated from 3 to 14 mg over eight weeks, versus placebo alongside usual treatment; 16-week study.
- Finding
- The model suggested more use of known high-reward choices, exploration of uncertain options and choice repetition. However, adjusted task-performance comparisons were not significant, and the parent trial found no executive-function benefit.
Full paper summarized · Verified intervention · Summary quality not appraised
Human · Randomized trial · 2026-10-20
Two randomized OSA subtrials tested retatrutide versus placebo, nested within larger phase 3 trials.
Population, studied exposure & key finding
- Population
- Adults with overweight/obesity and moderate-to-severe sleep apnea: 243 without and 448 with type 2 diabetes.
- Studied dose & duration
- Subcutaneous retatrutide 4, 9 or 12 mg once weekly versus placebo for 80 weeks; doses describe the study.
- Finding
- At 9 mg, placebo-adjusted AHI differences were −24.4 events/hour (95% CI −34.1 to −14.7) without diabetes and −14.4 (−21.6 to −7.2) with diabetes, using the hybrid estimand. Corresponding intention-to-treat differences were −24.7 and −13.9. Gastrointestinal events were most common.
Abstract summarized · Verified intervention · Summary quality not appraised
Human · Observational · 2026-10-12
A longitudinal cohort examined cardiac changes after continued or discontinued steroid use.
Population, studied exposure & key finding
- Population
- 70 men with steroid-use histories and 35 nonusing weightlifters returned for follow-up.
- Studied dose & duration
- Self-selected steroid use, cessation or continued abstinence; no standardized treatment regimen.
- Finding
- Continued users had ejection fraction 48 percent and indexed ventricular mass 119 g/m². Those stopping showed a six-percentage-point ejection-fraction improvement and 21 g/m² mass-index reduction.
Abstract summarized · Verified intervention · Summary quality not appraised
Human · Randomized trial · 2026-10-12
A crossover trial tested whether beetroot juice increased repetitions to failure.
Population, studied exposure & key finding
- Population
- Sixteen resistance-trained women.
- Studied dose & duration
- Juice with 12.8 mmol nitrate, placebo with 0.92 mmol, or no drink, 2.5 hours before bench and leg press at 60% of maximum.
- Finding
- Bench repetitions were 56.0 with nitrate versus 58.9 with placebo; leg-press repetitions were 79.3 versus 80.4. Differences were not significant. Exertion, heart rate, blood pressure and lactate also did not improve.
Abstract summarized · Verified intervention · Summary quality not appraised
Human · Randomized trial · 2026-10-09
A double-blind trial tested urolithin A effects on peripheral and brain vascular responses.
Population, studied exposure & key finding
- Population
- 50 middle-aged adults with obesity; 7 were lost to follow-up.
- Studied dose & duration
- Urolithin A 1000 mg versus placebo for 4 weeks.
- Finding
- The primary flow-mediated-dilation outcome and other peripheral vascular outcomes did not improve significantly. A secondary task-evoked brain-hemodynamic signal improved, while task performance remained unchanged.
Abstract summarized · Verified intervention · Summary quality not appraised
Human · Unclassified · 2026-10-09
An open-label extension followed weekly growth-hormone replacement.
Population, studied exposure & key finding
- Population
- 220 adults with GH deficiency who completed the parent trial.
- Studied dose & duration
- Weekly lonapegsomatropin for a 52-week extension after the 38-week parent trial. All received active treatment; exact doses were not in the abstract.
- Finding
- Body-composition improvements were maintained or improved relative to parent-trial baseline through up to 90 weeks. Injection-site reactions occurred in 5.1%, mild or moderate. Respiratory infections and headache were common events.
Abstract summarized · Verified intervention · Summary quality not appraised
Human · Randomized trial · 2026-10-08
NOPARK tested whether a NAD precursor improved early Parkinson disease outcomes.
Population, studied exposure & key finding
- Population
- 410 randomized participants; 393 in the primary analysis.
- Studied dose & duration
- Oral nicotinamide riboside 500 mg twice daily versus placebo for 52 weeks, alongside stable dopaminergic treatment.
- Finding
- The primary symptom score favored placebo: adjusted difference 2.72 points (95% CI 0.47–4.98), indicating greater worsening with NR. Four key secondary outcomes were null. Serious adverse events: 8.3% versus 14.1%.
Abstract summarized · Verified intervention · Summary quality not appraised